Renaissance Capital logo

CBYL News

No pain, more gains: Axsome Therapeutics files for a $58 million IPO

AXSM

Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. The company cites 2015 IPOs Carbylan Therapeutics (CBYL) and Flexion Therapeutics (FLXN) as potential competitors. The New York, NY-based company, which was founded...read more

US IPO Weekly Recap: 2 US IPOs feature first Chinese tech offering of 2015

Just two small and delayed IPOs - a Chinese e-commerce company and a biotech - raised $105 million this week as management typically avoids investor roadshows before Easter. The real action in the IPO market came from names like Party City (PRTY), Virtu Financial (VIRT) and Aduro Biotech (ADRO), which joined Etsy (ETSY) on next week's ...read more

Osteoarthritis pain biotech Carbylan Therapeutics prices upsized IPO at $5

CBYL

Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain in the knee, raised $65 million in an upsized IPO by offering 13 million shares (all primary) at $5. Carbylan originally planned to raise $75 million at a $211 million market cap in January, but postponed its IPO before revising its terms on Monday, with plans to offer 12 million shares...read more

Biotech Carbylan Therapeutics revives IPO, cuts offer price to $5

CBYL

Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain in the knee, revived terms for its IPO on Monday. The company, which had been looking to raise $75 million by offering 5.8 million shares at a price range of $12-$14 in January, is now seeking to raise $60 million by offering 12 million shares at $5 per share. At the midpoint of the...read more